ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NRBO NeuroBo Pharmaceuticals Inc

3.68
0.43 (13.23%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
NeuroBo Pharmaceuticals Inc NRBO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.43 13.23% 3.68 10:00:00
Open Price Low Price High Price Close Price Previous Close
3.43 3.35 3.68 3.68 3.25
more quote information »

Recent News

Date Time Source Heading
30/4/202422:01PRNUSNeuroBo to Present Latest Pre-Clinical Data on..
17/4/202422:05PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1..
01/4/202423:01PRNUSNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of..
28/3/202423:01PRNUSNeuroBo Pharmaceuticals Reports Year End 2023 Financial..
13/3/202423:01PRNUSNeuroBo Pharmaceuticals Receives Safety Review Committee..
05/3/202400:01PRNUSNeuroBo Pharmaceuticals Appoints Seasoned Life Science..
04/3/202423:30EDGAR2Form 8-K - Current report
01/3/202400:30EDGAR2Form 8-K - Current report
01/3/202400:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
15/2/202400:52EDGAR2Form 8-K - Current report
13/2/202400:01PRNUSNeuroBo Pharmaceuticals to Participate in the BIO CEO &..
02/2/202400:30EDGAR2Form 8-K - Current report
02/2/202400:01PRNUSNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a..
19/1/202400:30EDGAR2Form 8-K - Current report
19/1/202400:01PRNUSNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety..
10/1/202400:45EDGAR2Form 8-K - Current report
10/1/202400:30PRNUSNeuroBo Pharmaceuticals Regains Compliance with Nasdaq..
03/1/202400:01PRNUSNeuroBo to Participate in Industry and Investor Conferences..
29/12/202301:00EDGAR2Form 8-K - Current report
29/12/202300:45PRNUSNeuroBo Pharmaceuticals Submits IND Application to the FDA..
20/12/202301:03EDGAR2Form 8-K - Current report
20/12/202300:43PRNUSNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock..
08/12/202301:20EDGAR2Form 8-K - Current report
02/12/202300:31PRNUSNeuroBo to Participate in Investor Conferences in December
14/11/202308:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202308:14EDGAR2Form 8-K - Current report
14/11/202308:05PRNUSNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial..
07/11/202300:20EDGAR2Form 8-K - Current report
07/11/202300:05PRNUSNeuroBo Pharmaceuticals Strengthens Board of Directors with..
30/10/202323:06EDGAR2Form 8-K - Current report
17/10/202323:01PRNUSNeuroBo to Present at the H.C. Wainwright 7th Annual NASH..
22/9/202322:03EDGAR2Form 8-K - Current report
20/9/202306:15EDGAR2Form 8-K - Current report
15/9/202322:11EDGAR2Form 8-K - Current report
15/9/202322:01PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a..
25/8/202306:15EDGAR2Form 8-K - Current report
15/8/202306:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:18EDGAR2Form 8-K - Current report
14/8/202322:01PRNUSNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF..
10/8/202306:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:20EDGAR2Form 8-K - Current report
10/8/202306:05PRNUSNeuroBo Pharmaceuticals Reports Second Quarter 2023..
09/8/202306:15EDGAR2Form 8-K - Current report
03/8/202322:15EDGAR2Form 8-K - Current report
03/8/202322:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
02/8/202322:01PRNUSNeuroBo Pharmaceuticals Enters Into Term Sheet With MThera..
28/7/202320:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202320:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202320:02EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
29/6/202322:36EDGAR2Form 8-K - Current report

Your Recent History

Delayed Upgrade Clock